Information on the target
Alfasigma S.p.A. has continued its international growth through external lines by entering into an agreement with SEVER Life Sciences B.V. to acquire 100% of Nordic Group B.V. and its subsidiaries. Nordic Group, a specialty pharmaceutical company based in Hoofddorp, Netherlands, has a direct commercial presence in 18 European countries and operational platforms in Canada and Japan. In 2025, Nordic Pharma reported approximately €190 million in revenue and employs 265 staff members.
The transaction is expected to close by the end of the fourth quarter. Following the closing, SEVER Life Sciences will continue to develop its remaining activities, which include Sever Pharma Solutions AB, Farmaprim Srl, Esperante Development B.V., and Nordic Pharma Inc. The deal was initially announced on August 11, with further details on the advisors involved emerging recently.
Industry overview in the target’s specific country
The Proprietary & Advanced Pharmaceuticals industry in the Netherlands is characterized by a robust regulatory framework and a strong emphasis on innovation. The country is home to numerous pharmaceutical companies that are at the forefront of research and development, particularly in specialty areas such as oncology, immunology, and rare diseases. The Dutch government actively supports the pharmaceutical sector through various incentives, fostering an environment conducive to growth and investment.
In recent years, the Netherlands has seen a significant increase in investment in proprietary pharmaceuticals, driven by advancements in biotechnology and personalized medicine. This trend is supported by a well-established network of research institutions and universities that collaborate with industry players to bring innovative therapies to market. The presence of major pharmaceutical companies and a thriving startup ecosystem further enhances the country’s position as a leader in the European pharmaceutical landscape.
The market for proprietary pharmaceuticals in the Netherlands is also bolstered by a growing demand for specialty medications, particularly in areas such as rheumatology and women's health. As the population ages and the prevalence of chronic diseases increases, the need for advanced therapeutic solutions becomes more pronounced. This dynamic creates significant opportunities for companies like Nordic Pharma, which focus on niche markets with unmet medical needs.
Moreover, the Netherlands' strategic location within Europe facilitates access to a wide range of markets, making it an attractive hub for pharmaceutical companies looking to expand their operations. The combin…